Synthesis and Reactions of a New Class of Orally Active Pt(IV) Antitumor Complexes

  • Christen M. Giandomenico
  • Michael J. Abrams
  • Barry A. Murrer
  • Jean F. Vollano
  • Christopher F. J. Barnard
  • Kenneth R. Harrap
  • Phyllis M. Goddard
  • Lloyd R. Kelland
  • Sarah E. Morgan

Abstract

The advent of cisplatin was a breakthrough in the chemotherapy of certain cancers. Its success, in spite of adverse effects such as nephrotoxicity, nausea and vomiting, ototoxicity and myelosuppression, attests to its efficacy1. Still, the cost of treatment, in terms of patient quality of life, underscores the need for an efficacious drug with milder side effects. Carboplatin is an example of an agent specifically developed to reduce side effects while retaining the antitumor activity of cisplatin2. Its tremendous success, following its introduction in Europe and the US, attests to the importance of addressing patient quality of life. Although, oral chemotherapeutic agents are not presently a significant factor in cancer treatment, a properly designed agent could offer significant advantages in terms of a patients’ comfort and convenience, and anticipates the possibility of outpatient chemotherapy. At Johnson Matthey, in conjunction with the Institute of Cancer Research and Bristol-Myers Squibb, a portion of our platinum antitumor drug discovery program is devoted to the design and development of an orally active platinum antitumor drug. This paper describes the synthesis, reactions, and a few of the biological properties of a new class of antitumor agents that possess many characteristics required of an orally active antitumor agent.

Keywords

Antitumor Activity Antitumor Agent Mouse Tumor Model Mild Side Effect Lipophilic Side Chain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wiltshaw, E, presented at symposium Carboplatin: Current Status and Future Prospects. Stockholm, June 19, 1985.Google Scholar
  2. 2.
    Foster, B.J.; Harding, B. J.; Wolpert-DeFilippes, M.K.; Rubinstein, L.Y.; Clagett-Carr, K.; Leyland-Jones B. Canc. Chemo. Pharm. 1990,25, 395–404.CrossRefGoogle Scholar
  3. 3.
    Kararli, T.T. in Critical Reviews in Therapeutic Drug Carrier Systems 1989, 6, 39–86.PubMedGoogle Scholar
  4. 4.
    Sherman, S.E.; Gibson, D.; Wang, A.H.J.; Lippard, S.J. Science, 1985, 230, 412–17.PubMedCrossRefGoogle Scholar
  5. 5.
    Morgan, S.E.,; Boxall F.E.; Murrer, B.A.; Giandomenico C. M.; Wyer S.B.; Harrap, K.R. Sixth Intl. Symp. on Platinum and other Metal Coord. Compds., 1991, 229.Google Scholar
  6. 6.
    Prof. Jon Zubieta, Syracuse University, private communication.Google Scholar
  7. 7.
    Cowens, J.W.; Steive, F.A.; Alderfer, J.L; Hansen, G.E.; Pendyala, L.; Creaven, P.J. Int. J. Mass. Spect. Ion Phys. 1983,48, 177–80.CrossRefGoogle Scholar
  8. 8.
    Stephen G. Chancey, Steven Wyrick, Gail Kaun Till, Cancer Research, 1990, 50, 4539–4.Google Scholar
  9. 9.(a)
    Blatter, E.E., Vollano, J.F.; Krishna, B.S.; Dabrowiak, J.C. Biochemistry, 1984, 23, 4817.Google Scholar
  10. (b).
    Evans, J.E.; Green, M.; Inorg. Chim. Acta, 1987, 183-4.Google Scholar
  11. 10.
    Burchenal, J.H. et al Recent Results in Cancer Res. 1980, 74, 146.CrossRefGoogle Scholar
  12. 11.
    Kelland, L.R.; Abel, G.; Harrap, K.R. Proc. A.A.C.R., 1989, 609.Google Scholar
  13. 12.
    Binks, S.P; Dobrota, M. Biochemical Soc. Trans., 1986, 14, 694–5.Google Scholar
  14. 13.
    Morgan, S.E.; Webster, L.K.; Boxall, F.E.; Siddik, Z.H.; Murrer, B.A.; Harrap K.R. presented in Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy, 1989.Google Scholar
  15. 14.
    Goddard, P.M., Valenti, M.R., Murrer, B.A., Harrap K.R., presented in Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy, 1989.Google Scholar
  16. 15.
    Harrap, K.R. Cancer Treat. Rev., 1985, 21-33.Google Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Christen M. Giandomenico
    • 1
  • Michael J. Abrams
    • 1
  • Barry A. Murrer
    • 2
  • Jean F. Vollano
    • 1
  • Christopher F. J. Barnard
    • 2
  • Kenneth R. Harrap
    • 3
  • Phyllis M. Goddard
    • 3
  • Lloyd R. Kelland
    • 3
  • Sarah E. Morgan
    • 3
  1. 1.Johnson Matthey Biomedical ResearchWest ChesterUSA
  2. 2.Johnson Matthey Technology CentreReadingUK
  3. 3.Institute of Cancer ResearchBelmont, Sutton, SurreyUK

Personalised recommendations